Loading clinical trials...
Loading clinical trials...
The objective of this study was to investigate the current situation of vancomycin (VAN)-associated acute kidney injury (VA-AKI) in China and identify the risk factors for VA-AKI, as well as to comprehensively examine the risk related to concurrent drug use. Further, the investigators assessed the outcomes of patients who developed VA-AKI and the risk factors for these outcomes. Finally, the investigators aimed to provide suggestions for improving the prevention and treatment of VA-AKI in China.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Peking University First Hospital
Beijing, Beijing Municipality, China
Start Date
October 31, 2018
Primary Completion Date
October 31, 2019
Completion Date
December 31, 2019
Last Updated
August 28, 2019
10,000
ESTIMATED participants
Vancomycin
DRUG
Lead Sponsor
Peking University First Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT02456974